di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico
Universitario “A. Gemelli”, IRCCS, Rome, Italy.
2 Dipartimento di Scienze biotecnologiche di base, cliniche intensivologiche e perioperatorie – Sezione di Microbiologia, Università Cattolica del Sacro Cuore, Rome, Italy.
3 Mater Olbia Hospital, Olbia, Italy.
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
the emergence of Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) at the end of 2019, a number of medications have been used
to treat the infection and the related Coronavirus disease – 19
Therapies Against SARS-CoV-2 Infection
|Figure 1. Schematic representation of the pharmaceuticals used against SARS-CoV-2 infection. The first class of molecules includes antivirals to prevent viral entry (point 1); the second class includes compounds that inhibit gene transcription (point 2) and the third class accounts molecules that prevent proteolytic processing and block viral docking (point 3). The points 4-6 described medications that reduce tissue damage, modulating the immune responses or preventing over-inflammation.|
|Table 1. Summary reporting experimental evidence of the impact of drugs used against SARS-CoV-2 infection on Mycobacterium tuberculosis infection.|
Impact of the Therapies Against SARS-CoV-2 on Mycobacterium tuberculosis
|Figure 2. Schematic representation of the medications used against SARS-CoV-2 with effects on Mycobacterium tuberculosis infection. Therapies used against COVID-19 are classified based on their activity on Mtb infection in four main classes: drugs acting directly on mycobacteria (point 1) or indirectly showing ability to modify phagosome acidification (point 2), to modulate the infection with adjuvant functions (point 3) and to regulate hose immune response (point 4).|